首页> 外文期刊>Critical reviews in toxicology >Sulfur mustard and respiratory diseases: Revisit with special reference to the 'Comments on 'Sulfur Mustard and Respiratory Diseases', Tang and Loke (2012) and a prepared Integrated Mechanism for Chronic Pulmonary Disease from Exposure to Sulfur Mustard' by Saburi and Ghanei (2013)
【24h】

Sulfur mustard and respiratory diseases: Revisit with special reference to the 'Comments on 'Sulfur Mustard and Respiratory Diseases', Tang and Loke (2012) and a prepared Integrated Mechanism for Chronic Pulmonary Disease from Exposure to Sulfur Mustard' by Saburi and Ghanei (2013)

机译:硫芥子和呼吸系统疾病:特别参考Saburi和Ghanei(2013年,Tang和Loke的“关于“硫芥子和呼吸系统疾病的评论”,Tang and Loke(2012年)和从暴露于硫芥子的慢性肺病的综合机制”进行回顾)

获取原文
获取原文并翻译 | 示例
       

摘要

We have read with some interest the comments by Saburi & Ghanei (2013) on our recent publication entitled "Sulfur mustard and respiratory diseases" (Tang & Loke, 2012) published in Critical Reviews in Toxicology. Here are our replies to their concerns.In Section 5.2. "HD-induced chronic damages", pp. 696-697, we have elaborated possible mechanisms involved in pathogenesis of mustard-induced chronic respiratory disease. Based on experimental data provided by various research groups, we have also mentioned at least six potential drug targets that could lead to a treatment solution for chronic phase respiratory effects (Tang & Loke, 2012). While highlighting these possible therapeutic approaches, it is important to note that most of the available clinical data (Ghanei et al., 2004, 2005, 2006, 2007; Panahi et al., 2005) were obtained from non-Randomized Clinical Trials (RCT), which has limited sample sizes, lacked case controls and double-blind randomized trial designs.
机译:我们对Saburi&Ghanei(2013)对我们最近出版的《硫芥子和呼吸系统疾病》(Tang&Loke,2012年)发表在《毒理学评论》中的评论颇有兴趣。这是我们对他们所关注问题的答复。在5.2节中。第696-697页,“ HD引起的慢性损害”,我们已经详细阐述了芥子诱导的慢性呼吸道疾病发病机理中涉及的可能机制。根据各个研究小组提供的实验数据,我们还提到了至少六个潜在的药物靶标,这些靶标可能会导致慢性呼吸道疾病的治疗方案(Tang&Loke,2012)。在强调这些可能的治疗方法的同时,重要的是要注意,大多数可用的临床数据(Ghanei等,2004、2005、2006、2007; Panahi等,2005)均来自非随机化临床试验(RCT)。 ),样本量有限,缺乏病例对照和双盲随机试验设计。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号